Helius Medical Technologies Inc. has filed an updated Prospectus Supplement on July 7, 2025, to offer and sell up to $25 million of its common stock shares through Roth Capital Partners, LLC, as sales agent. This move follows a Sales Agreement entered on June 23, 2023. The shares, registered under the Securities Act of 1933, will be available for sale through various methods, including direct sales on The Nasdaq Global Market. The proceeds from the stock offering are intended to support the company's working capital and general corporate purposes, such as commercialization efforts and research and development activities. Legal counsel for the company, Honigman LLP, has provided an opinion on the shares, which is included as an exhibit in the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。